CN-122017249-A - Biomarker for identifying major depressive disorder multiple groups and application thereof

Abstract

The invention relates to a biomarker for identifying multiple groups of chemical subtypes of major depressive disorder and application thereof, wherein the multiple groups of chemical subtypes of major depressive disorder are a MoS1 subtype, a MoS2 subtype and a MoS3 subtype respectively, the biomarker for identifying the MoS1 subtype comprises IGFBP-2, met, clinical_monocytes, B and Sperminine, the biomarker for identifying the MoS2 subtype comprises SPERMIDINE, SDMA and TG.16.1_32.2, cys, and the biomarker for identifying the MoS3 subtype comprises Monocytes, CD4, HLADR_ Monocytes, active_Treg and CD36_Treg. A good balance of sensitivity and specificity is achieved at the optimal threshold, showing good diagnostic efficacy.

Inventors

• LI HUAFANG
• ZENG DUAN
• HE SHEN

Assignees

• 上海市精神卫生中心（上海市心理咨询培训中心）

Dates

Publication Date

20260512

Application Date

20260128

Claims (4)

1. 1. A biomarker for identifying a major depressive multi-component subtype, wherein the major depressive multi-component subtype is a MoS1 subtype, a MoS2 subtype, and a MoS3 subtype, respectively; Biomarkers for identifying the MoS1 subtype include IGFBP-2, met, clinical_Monocytes, B, spermid; biomarkers for identifying MoS2 subtype include SPERMIDINE, SDMA, tg.16.1_32.2, cys; biomarkers for identifying the MoS3 subtype include Monocytes, CD4, hladr_ Monocytes, activated_treg, cd36_treg.
2. 2. The biomarker of claim 1, wherein the different subtypes have significant differences in the effectiveness of antidepressant treatment, with the most effective treatment of the MoS1 subtype and the least effective treatment of the MoS3 subtype and the MoS2 subtype.
3. 3. Use of an agent that detects the level of a biomarker of claim 1 in the manufacture of a product for identifying multiple chemical subtypes of major depressive disorder.
4. 4. The use according to claim 3, wherein, Diagnostic model for MoS1 subtype ; Diagnostic model for MoS2 subtype ; Diagnostic model for MoS3 subtype 。

Description

Biomarker for identifying major depressive disorder multiple groups and application thereof Technical Field The invention belongs to the technical field of mental disease diagnosis, in particular to the technical field of major depressive disorder diagnosis, and particularly relates to a biomarker for identifying multiple groups of chemical subtypes of major depressive disorder and application thereof. Background Major Depressive Disorder (MDD) is a globally common high-disability mental disorder affecting more than 3 hundred million people, causing a heavy burden to both individuals and society. However, depression is not a single disease entity, but a syndrome with significant clinical and biological heterogeneity whose etiology involves diverse pathophysiological mechanisms and manifests itself in a broad spectrum of symptoms. This heterogeneity leads to an insufficient accuracy of the current diagnostic framework, which in turn affects treatment response prediction and intervention strategy selection. Therefore, the identification of the subtype of depression with different biological basis is of great importance for achieving more accurate diagnosis and personalized treatment. It is difficult to adequately reveal the high heterogeneity of depression based on single or few biomarkers. The multi-group technology provides a powerful means for analyzing the heterogeneity of the disease and identifying its potential subtypes by integrating multi-level biological information. Currently, research for exploring depression subtypes using multiple sets of chemical data is still very limited. Hagenberg et al integrate 43 plasma immune markers with transcriptome data, identifying four subgroups, two of which are closely related to immune-related symptom populations. Joyce et al found that combining metabolomics with pharmacogenomic data was more effective in predicting antidepressant treatment responses than metabolomics alone. Tang et al define three major depressive subtypes based on neuroimaging and further illustrate the biological features behind them using multiple sets of data. Although some of the subtypes of depression have been initially identified through multiple-genetics approaches, how to effectively integrate multidimensional data to facilitate personalized diagnosis, treatment, and prognostic assessment of depression remains a key challenge currently faced. There is growing evidence that the development and progression of depression is intimately linked to inflammatory responses, immune dysfunction and metabolic disorders. Significant immune metabolic disorders can be observed in about 20% -30% of depressed patients. Metabolic abnormalities and dyslipidemia can exacerbate neuroinflammation through vascular dysfunction, oxidative stress, and other mechanisms, thereby exacerbating depression and anxiety symptoms. At the inflammatory level, studies have found that elevated levels of peripheral blood cytokines in depressed patients are correlated with their response to antidepressant therapy. The above studies suggest that the incorporation of inflammatory, immune, and metabolic regulation into a personalized antidepressant therapeutic strategy has significant potential. The multi-dimensional histology integration module study (iMORE) of the peripheral biomarker is a prospective observational queue study established by the research and development team of the inventor, and aims to systematically integrate multiple sets of metabonomics, cytokines, immunophenotype and other data. Based on this, subtype analysis was performed on depression using the multiple sets of mathematical data of iMORE cohorts to explore its relationship with therapeutic response and provide basis for developing new therapeutic strategies. Disclosure of Invention The main object of the present invention is to provide a biomarker for identifying multiple groups of chemical subtypes of major depressive disorder and application thereof, aiming at the problems existing above. In order to achieve the above object, a first aspect of the present invention provides a biomarker for identifying major depressive multi-group chemical subtypes, which is mainly characterized in that the major depressive multi-group chemical subtypes are respectively a MoS1 subtype, a MoS2 subtype and a MoS3 subtype; Biomarkers for identifying the MoS1 subtype include IGFBP-2, met, clinical_Monocytes, B, spermid; biomarkers for identifying MoS2 subtype include SPERMIDINE, SDMA, tg.16.1_32.2, cys; biomarkers for identifying the MoS3 subtype include Monocytes, CD4, hladr_ Monocytes, activated_treg, cd36_treg. Preferably, the different subtypes have significant differences in the effectiveness of antidepressant therapy. Of these, the MoS1 subtype is most therapeutically effective, the MoS3 subtype is less effective, and the MoS2 subtype is least effective. Antidepressants are commonly used antidepressants, for example selective 5-hydroxytryptamine reuptake inhibitor